Search | Clinical Trials Finder

Conditions: Prostate Cancer
Interventions: Best Systemic Therapy (BST), Best Systemic Therapy (BST) + Surgery or Radiation Therapy, Questionnaires, Phone Call/Email; Other · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 3
States / cities: San Francisco, California • Philadelphia, Pennsylvania • Houston, Texas

Conditions: Leukemia, Myeloid, Acute
Interventions: Oral Azacitidine, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 55 Years and older
Enrollment: 472 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 60
States / cities: Phoenix, Arizona • Burbank, California • Duarte, California + 48 more

Conditions: Retinitis Pigmentosa
Interventions: N-acetylcysteine, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 24
States / cities: Davis, California • Los Angeles, California • San Francisco, California + 21 more

Conditions: Neovascular Age-related Macular Degeneration
Interventions: ADVM-022; Genetic
Lead sponsor: Adverum Biotechnologies, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 34
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 30 more

Conditions: Mild Traumatic Brain Injury, Alexithymia
Interventions: Program 1, Program 2; Behavioral
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: Indianapolis, Indiana • Bethesda, Maryland • Edison, New Jersey

Conditions: Carcinoma
Interventions: Everolimus, Everolimus Placebo, Best Supportive Care (BSC); Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 19
States / cities: Fayetteville, Arkansas • Fountain Valley, California • La Jolla, California + 15 more

Conditions: Stage IV Resectable Melanoma
Interventions: Surgery, Surgery plus 2 adjuvant doses of BCG, best medical therapy; Procedure · Other
Lead sponsor: Saint John's Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 15
States / cities: Sacramento, California • Santa Monica, California • Chicago, Illinois + 11 more

Conditions: Oral Mucositis
Interventions: Chemo Mouthpiece, Best Supportive Care only; Device · Other
Lead sponsor: Chemo Mouthpiece; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 11
States / cities: Costa Mesa, California • Goshen, Indiana • Farmington Hills, Michigan + 8 more

Conditions: Cardiac Arrest, Out-Of-Hospital
Interventions: CPR Training, CPR Manikin Type; Behavioral · Device
Lead sponsor: University of Nevada, Reno; Other
Eligibility: Not listed
Enrollment: 2,100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Reno, Nevada

Conditions: Hematologic Neoplasms
Interventions: Assessment Surveys, Qualitative Interviews; Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 60 Years and older
Enrollment: 51 participants
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Low Vision, Low Vision Aids
Interventions: Low Vision Rehabilitation; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 9
States / cities: Fullerton, California • Grass Valley, California • Los Angeles, California + 6 more

Conditions: Diabetes, Hyperglycemia
Interventions: Best Practice Advisory; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: Not listed
Enrollment: 7,232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Metastatic Colorectal Cancer, Colorectal Cancer
Interventions: MORAb-004, Placebo, Best supportive care; Drug · Other
Lead sponsor: Morphotek; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 67
States / cities: Alhambra, California • Bakersfield, California • Burbank, California + 54 more

Conditions: Colorectal Cancer
Interventions: TAS-102, Placebo; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 23
States / cities: Glendale, Arizona • Fresno, California • Gilroy, California + 18 more

Conditions: Disease, Hodgkin
Interventions: brentuximab vedotin, placebo; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 32
States / cities: Duarte, California • San Francisco, California • Stanford, California + 26 more

Conditions: GVHD
Interventions: Apraglutide; Drug
Lead sponsor: VectivBio AG; Industry
Eligibility: 12 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 5
States / cities: Stanford, California • Iowa City, Iowa • Boston, Massachusetts + 2 more

Conditions: Bronchiolitis
Interventions: Non-interruptive, Interruptive; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: Up to 24 Months
Enrollment: 2,965 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: St. Petersburg, Florida • Baltimore, Maryland

Conditions: IBS - Irritable Bowel Syndrome
Interventions: Registered dietitian, On-line video program, Printed handout, Dietitian-led group; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Posttraumatic Stress Disorder
Interventions: Prolonged Exposure Therapy, Pharmacotherapy with paroxetine or venlafaxine XR; Behavioral · Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 75 Years
Enrollment: 304 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 7
States / cities: Birmingham, Alabama • Menlo Park, California • San Diego, California + 4 more

Conditions: Corneal Edema, Corneal Endothelial Dysfunction, Fuchs Endothelial Corneal Dysfunction, Pseudophakic Bullous Keratopathy (PBK)
Interventions: Combination Product: AURN001 + Y-27632, Placebo; Drug · Other
Lead sponsor: Aurion Biotech; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 12
States / cities: Mesa, Arizona • Little Rock, Arkansas • Fort Collins, Colorado + 9 more

Conditions: Macular Degeneration, Geographic Atrophy, Stargardt Disease
Interventions: Observational; Other
Lead sponsor: Nanoscope Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Graft-versus-host Disease (GVHD)
Interventions: Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 38
States / cities: Tucson, Arizona • Duarte, California • La Jolla, California + 28 more

Conditions: Sickle Cell Disease
Interventions: Community Health Worker (CHW), Education; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 10 Years to 18 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: New York, New York • The Bronx, New York

Conditions: Solid Tumors, Breast Cancer, Neoplasms
Interventions: SU011248; Capecitabine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 3
States / cities: Indianapolis, Indiana • Albuqurque, New Mexico • Nashville, Tennessee

Search by objective public record fields.

Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery)

Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission

Oral N-acetylcysteine for Retinitis Pigmentosa

Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]

Clinical Trial Comparing the Efficacy of Two Teletherapy Programs at Improving Psychological Health in People With Brain Injury

Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.

Stage IV Surgery Versus Best Medical Therapy

A Trial Assessing Chemo Mouthpiece Device With Best Supportive Care for Symptoms of Chemotherapy-Induced Oral Mucositis

Gathering Evidence on Best Practices for Lay Rescuer CPR Training

Understanding What Matters Most to Patients: Establishing the Validity of a Best-Worst Scaling Survey

Beacon Sensors and Telerehabilitation to Assess and Improve Use of Devices (BeST-AID) for Low Vision

Comparison of Intraoperative Best Practice Advisory Reminders to Protocolize Insulin Administration Versus Standard Care in Patients at High Risk of Hyperglycemia

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)

Evaluation of the Impact of EHR-Alerts on Clinical Decision Support Pathway Use in Bronchiolitis, and the Impact of Pathway Use on the Prescription of High Flow Nasal Cannula and Other Elements of High Value Care.

Implementing a Low FODMAP Diet in Irritable Bowel Syndrome Patients

A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD

AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction

A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment: HABIT

A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together